Almirall SA traded at 10.53 this Friday May 20th, increasing 0.16 or 1.54 percent since the previous trading session. Looking back, over the last four weeks, Almirall SA gained 12.90 percent. Over the last 12 months, its price fell by 24.79 percent. Looking ahead, we forecast Almirall SA to be priced at 10.11 by the end of this quarter and at 9.18 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
10.53
Daily Change
1.54%
Yearly
-24.79%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Amadeus IT 59.72 1.18 2.02% -0.33%
Cie Automotive 21.52 0.42 1.99% -11.29%
Ence Energia y Celulosa SA 3.54 0.02 0.68% 1.08%
Genmab 2,167.00 41.00 1.93% -5.58%
GRIFOLS 19.99 0.08 0.38% -14.23%
Inditex 20.50 0.21 1.03% -36.75%
Lonza Group 553.40 19.60 3.67% -2.54%
H Lundbeck A/S 166.60 -0.45 -0.27% -13.57%
Melia Hotels 6.96 0.06 0.80% 4.07%
Orion 37.27 0.25 0.68% 1.47%
Recordati 42.14 0.63 1.52% -9.36%
Tecnicas Reunidas 9.59 0.10 1.00% -19.32%
UCB 87.92 -1.84 -2.05% 13.45%
Viscofan 49.56 0.02 0.04% -15.64%

Indexes Price Day Year
ES35 8487 81.34 0.97% -7.79%

Almirall SA
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.